



The second recurrence of *Mycobacterium avium* complex lung disease after successful treatment for first recurrence

To the Editor:

The recurrence rate of *Mycobacterium avium* complex (MAC) lung disease (LD) after successful treatment is approximately 10–48% [1–3]. These episodes represent true relapse from the same MAC strain or a reinfection with a new strain [1, 2, 4]. Nodular bronchiectatic (NB) type, old age, lower body mass index (BMI) and *M. avium* isolates are related to recurrence [3, 5, 6].

However, information on the clinical course of MAC-LD after successfully treating the first recurrence is limited [7]. We therefore investigated the second recurrence in patients with MAC-LD who were successfully treated for the first recurrence, with a focus on the rate and treatment outcomes of second recurrence, and its predictors.

We categorised radiological abnormalities into three groups: 1) cavitory NB, 2) noncavitory NB and 3) fibrocavitory (FC), as previously defined [5, 8]. Only the patients who received treatment for ≥ 12 months were analysed for treatment response. Treatment outcomes were categorised as follows [9]. 1) Treatment failure: no conversion to negative sputum culture even after ≥ 12 months of treatment; 2) treatment completion: achievement of sputum culture conversion with a treatment duration after conversion of < 12 months; 3) treatment success: achievement of sputum culture conversion with a treatment duration after conversion of ≥ 12 months. Recurrence was defined as two consecutive positive sputum cultures after treatment success.

Between March 2000 and August 2017, 104 patients who experienced first recurrence of MAC-LD, amongst the 372 patients who achieved treatment success for MAC-LD, were identified at the Asan Medical Center in Seoul, South Korea. Of these 104 patients, clinical symptom deteriorations were noted in 61 (58.7%) patients and radiological changes were noted in 62 (59.6%) patients. Of 104 patients, 55 (52.9%) patients received anti-MAC treatment. The most common radiological finding was the noncavitory NB type, which was observed in 39 (70.9%) patients. Daily therapy comprising macrolides, ethambutol and rifamycin was the most commonly prescribed regimen. The overall success rate of treatment of the first recurrence was 61.8% (34 out of 55).

Amongst the 34 patients who achieved treatment success after the first recurrence of MAC-LD, 20 (58.8%) experienced a second recurrence during the median follow-up of 15.2 months (interquartile range (IQR) 7.7–26.4 months). The aetiological agent was *M. avium* in 12 (60.0%) patients and *Mycobacterium intracellulare* in eight (40.0%) patients. Amongst the 20 patients, deterioration in the radiological changes and clinical symptoms were observed in 16 (80%) and nine (45%) patients. A drug susceptibility test was performed in 85% of the patients (17 out of 20); no macrolide-resistant cases were detected.

Amongst the 20 patients with second recurrence, nine (45%) patients received anti-MAC treatment. Radiological features included the noncavitory NB type in seven (77.8%) patients, the cavitory NB type in one (11.1%) patient and the FC type in one (11.1%) patient. Radiological deterioration was noted in all nine patients and the symptoms worsened in five patients. Furthermore, eight patients were treated with daily therapy comprising macrolides (azithromycin for seven patients and clarithromycin for one patient), ethambutol and rifamycin (rifampicin or rifabutin), with or without moxifloxacin. The remaining patient



@ERSpublications

Approximately 60% of patients who are successfully treated for their first recurrence of MAC lung disease eventually experience a second recurrence. Approximately half of the second recurrence patients require anti-MAC treatment. <http://ow.ly/3G2R30meImC>

Cite this article as: Kwon BS, Shim TS, Jo K-W. The second recurrence of *Mycobacterium avium* complex lung disease after successful treatment for first recurrence. *Eur Respir J* 2019; 53: 1801038 [<https://doi.org/10.1183/13993003.01038-2018>].

received a combination of daily azithromycin, rifabutin, clofazimine and moxifloxacin due to a previous history of optic neuropathy caused by ethambutol. All nine patients were administered streptomycin three to five times per week *via* intramuscular injections for a median duration of 4.8 months (IQR 3.8–7.3 months). The treatment outcomes for the second recurrence were: treatment success, 44.4% (four out of nine); treatment completion, 11.1% (one out of nine); and treatment failure, 44.4% (four out of nine).

An analysis of factors related to the second recurrence revealed no significant differences based on the radiological type. That is, amongst the 34 patients who achieved treatment success for the first recurrence, a second recurrence occurred in 58.6% (17 out of 29) of the NB type and 60.0% (three out of five) of the FC type ($p=0.955$) (figure 1). No other clinical variables were significant factors of the second recurrence.

To the best of our knowledge, this is the first study to investigate the rate of second recurrence after successful treatment of the first recurrence of MAC-LD, its predictors and treatment outcomes. Our findings reveal several important clinical implications. First, even after successful treatment of the first episode of recurrence, secondary episodes of MAC-LD recurrence were also frequent. We found that ~60% of patients who were successfully treated for the first recurrence eventually experienced a second recurrence, which suggests that the recurrence of MAC can occur repeatedly in a substantial proportion of patients. The most probable explanation for repetitive recurrence is reinfection caused by unavoidable exposure to environmental sources, such as water and soil [10]. This is a particular issue in subjects with host immune deficiencies, which predisposes individuals to pulmonary MAC infections [11]. Reinfection has been reported to occur more often than true relapse in MAC-LD [2, 4, 5, 7].

The second important finding is that approximately half of the patients with secondary recurrence required anti-MAC treatment, with unsuccessful outcomes; the treatment success rate was less than half, although all patients received macrolide-containing regimens that included aminoglycoside. The reason for this low treatment success rate appears unclear given that there were no cases of macrolide resistance, and only two cases displayed the cavitory form of the disease. Recently, JHUN *et al.* [12] found that refractory MAC-LD is commonly caused by reinfection with new strains. In their study, amongst 49 patients with refractory MAC-LD whose pre- and post-treatment isolates were stored, genotyping revealed that reinfection by new MAC strains occurred in 36 (73%) patients. Only 13 (27%) patients had persistent infections with their original strains. We thought that reinfection with new MAC strains could be the most plausible reason for the low treatment success rate in the present study. In this light, the statement from the British Thoracic Society guidelines is noteworthy: “If available, genotyping may help distinguish relapse from reinfection” [13]. We believe that this statement can be applied to any cases with first or second recurrence for identifying the cause and preparing an appropriate treatment regimen.

In addition to radiological type, previous studies have reported that older age, lower BMI and *M. avium* isolates were associated with the first recurrence of MAC-LD [6]. However, none of these variables were related to a second recurrence in our study. This could be attributed to the small sample size, warranting further studies with a sufficient number of patients to identify factors related to the second recurrence in similar cases.

Our study has several limitations. Our study was a retrospective study performed at a single centre with small sample size. Moreover, seven patients experienced a first recurrence but failed to follow up. Although the number of patients lost to follow-up was small, this may have affected the results. Additionally, we did




FIGURE 1 Kaplan–Meier curves of the cumulative rate of second recurrence in patients successfully treated for the first recurrence of *Mycobacterium avium* complex lung disease. NB: nodular bronchiectasis; NC: noncavitory; CNB: cavitory nodular bronchiectasis; FC: fibrocavitory.

not have any apparent algorithm or criteria to determine treatment initiation for patients who experienced recurrence. Moreover, the treatment regimen was decided by the attending clinicians without a constant protocol. Finally, and most importantly, we did not genotype the isolates; therefore, we could not distinguish the difference between relapse and reinfection in our cases.

In conclusion, we found that ~60% of patients who achieved successful treatment for the first recurrence of MAC-LD eventually experienced a second recurrence. Approximately half of the second recurrence patients required anti-MAC treatment, with unsatisfactory outcomes.

Byoung Soo Kwon, Tae Sun Shim and Kyung-Wook Jo

Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

Correspondence: Kyung-Wook Jo, Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.

E-mail: heathcliff6800@hanmail.net

Received: June 03 2018 | Accepted after revision: Oct 08 2018

Conflict of interest: None declared.

References

- 1 Boyle DP, Zembower TR, Qi C. Relapse versus reinfection of *Mycobacterium avium* complex pulmonary disease. Patient characteristics and macrolide susceptibility. *Ann Am Thorac Soc* 2016; 13: 1956–1961.
- 2 Wallace RJ Jr, Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic *Mycobacterium avium* complex lung disease. *Chest* 2014; 146: 276–282.
- 3 Lee BY, Kim S, Hong Y, et al. Risk factors for recurrence after successful treatment of *Mycobacterium avium* complex lung disease. *Antimicrob Agents Chemother* 2015; 59: 2972–2977.
- 4 Wallace RJ Jr, Zhang Y, Brown-Elliott BA, et al. Repeat positive cultures in *Mycobacterium intracellulare* lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. *J Infect Dis* 2002; 186: 266–273.
- 5 Koh WJ, Moon SM, Kim SY, et al. Outcomes of *Mycobacterium avium* complex lung disease based on clinical phenotype. *Eur Respir J* 2017; 50: 1602503.
- 6 Boyle DP, Zembower TR, Reddy S, et al. Comparison of clinical features, virulence, and relapse among *Mycobacterium avium* complex species. *Am J Respir Crit Care Med* 2015; 191: 1310–1317.
- 7 Jhun BW, Moon SM, Kim SY, et al. Intermittent antibiotic therapy for recurrent nodular bronchiectatic *Mycobacterium avium* complex lung disease. *Antimicrob Agents Chemother* 2018; 62: e01812-17.
- 8 Hwang JA, Kim S, Jo KW, et al. Natural history of *Mycobacterium avium* complex lung disease in untreated patients with stable course. *Eur Respir J* 2017; 49: 1600537.
- 9 Kwon BS, Kim MN, Sung H, et al. *In vitro* minimal inhibitory concentrations of rifampin and ethambutol, and treatment outcome in *Mycobacterium avium* complex lung disease. *Antimicrob Agents Chemother* 2018; 62: AAC 00491-18.
- 10 Nishiuchi Y, Iwamoto T, Maruyama F. Infection sources of a common non-tuberculous mycobacterial pathogen, *Mycobacterium avium* complex. *Front Med (Lausanne)* 2017; 4: 27.
- 11 Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. *Lancet Infect Dis* 2015; 15: 968–980.
- 12 Jhun BW, Kim SY, Moon SM, et al. Development of macrolide resistance and reinfection in refractory *Mycobacterium avium* complex lung disease. *Am J Respir Crit Care Med* 2018; 198: 1322–1330.
- 13 Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). *Thorax* 2017; 72: ii1–ii64.

Copyright ©ERS 2019